Program
autogene cevumeran
Also written as “Autogene cevumeran”, “Autogene Cevumeran” and “RO7198457 intravenous (IV)”.
Its studies are mostly in Melanoma · Colorectal Neoplasms · Adenocarcinoma, led by 2 companies.
Drug pageAutogene cevumeran: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 42 open or running | phase 2since Jan 7, 2019 | Sep 19, 2017 | Nov 10, 2027phase 2 · NCT06534983 |
| BioNTech | 11 open or running | phase 2since Jul 20, 2020 | Jul 20, 2020 | Nov 2026phase 2 · NCT04486378 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6180 autogene cevumeran (BioNTech)
, phase 2, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of BioNTech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named autogene cevumeranINNProposed as its International Nonproprietary Name in WHO's List 122
- Jul 20, 2020First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT04486378 · 327 enrolled · United States, Belgium, Canada and more
Ahead
- Nov 2026Primary completion: phase 2 study in Colorectal NeoplasmsNCT04486378
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up…”NCIt, read by Claude
Studies
The one study BioNTech leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04486378Colorectal Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Nov 2026 | 327 |
How it is read
Names in the registry
- “Autogene cevumeran”, 3 entries
- “Autogene Cevumeran”, 1 entry
- “RO7198457 intravenous (IV)”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 2 studies
- Colorectal Neoplasms, 1 study
- Adenocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.